Company Analysis
Sign in

Cardiff Oncology, Inc. (CRDF)

Nasdaq: CRDF · Biological Products, (No Diagnostic Substances) · San Diego, CA · filing with the SEC since 2003
Full chart Alerts Compare
Grade4.4
◀ Past 4.9● Present 3.7▶ Future 4.8
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

17 patents granted to the 5 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Cardiff Oncology, Inc.’s names, not what it holds today.

Patents granted
17
16 utility, 1 reissue, 1976 to Dec 31, 2025
Granted in 2025
1
Against 2 in 2024 and none in 2023
Applications published
42
6 of them in 2025
Names they are printed under
5
a former name, its own name
By yearGrantedApplications published
'07'10'11'12'13'14'15'16'17'18'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals3
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name5 counted
Trovagene, Inc. a former name
US, as the owner printed on each patent
13 granted
11 published
Cardiff Oncology, Inc. its own name
named as the applicant on its applications, in US
0 granted
22 published
Trovagene, Inc. a former name
named as the applicant on its applications, in US
0 granted
8 published
Cardiff Oncology, Inc. its own name
US, as the owner printed on each patent
3 granted
0 published
Xenomics, Inc. a former name
US, as the owner printed on each patent
1 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Apr 1, 202512,263,173PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancerPharmaceuticalsCardiff Oncology, Inc.
Nov 19, 202412,144,813PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancerPharmaceuticalsCardiff Oncology, Inc.
Apr 16, 202411,957,677Cancer treatment using FGFR inhibitors and PLK1 inhibitorsPharmaceuticalsCardiff Oncology, Inc.
Mar 6, 20189,909,118Compositions, methods and kits for isolating nucleic acids from body fluids using anion exchange mediaBiotechnologyTrovagene, Inc.
Nov 14, 20179,816,148Amplification and sequencing of transrenal nucleic acidsBiotechnologyTrovagene, Inc.
Aug 8, 20179,725,767Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereofBiotechnologyTrovagene, Inc.
Aug 8, 20179,725,755Synthesis and enrichment of nucleic acid sequencesBiotechnologyTrovagene, Inc.
Sep 27, 20169,453,265Method for detection of high risk human papillomavirusBiotechnologyTrovagene, Inc.
Dec 29, 20159,222,137Method for monitoring minimal residual hairy cell leukemiaBiotechnologyTrovagene, Inc.
Oct 20, 20159,163,229Compositions, methods and kits for isolating nucleic acids from body fluids using anion exchange mediaBiotechnologyTrovagene, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Sep 4, 20252025/0275978USE OF ONVANSERTIB AS MONOTHERAPY AND IN COMBINATION WITH CETUXIMAB IN TREATING RAS WILD-TYPE COLORECTAL CANCERPharmaceuticalsCardiff Oncology, Inc.
Jul 10, 20252025/0223348PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCERPharmaceuticalsCardiff Oncology, Inc.
Mar 27, 20252025/0101092PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCERPharmaceuticalsCardiff Oncology, Inc.
Feb 20, 20252025/0057847PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCERPharmaceuticalsCardiff Oncology, Inc.
Jan 30, 20252025/0032495PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCERPharmaceuticalsCardiff Oncology, Inc. · patent 12,263,173 granted from it
Jan 16, 20252025/0017933CANCER TREATMENT USING LSD1 INHIBITORS AND PLK1 INHIBITORSPharmaceuticalsCardiff Oncology, Inc.
Oct 24, 20242024/0352115PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCERPharmaceuticalsCardiff Oncology, Inc.
Oct 24, 20242024/0352114PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCERPharmaceuticalsCardiff Oncology, Inc.
Oct 24, 20242024/0350500PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCERPharmaceuticalsCardiff Oncology, Inc.
Oct 24, 20242024/0350499PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCERPharmaceuticalsCardiff Oncology, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 13.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton CRDF · research, not advice